4D Molecular Therapeutics Inc — Cash Flow (NASDAQ:FDMT) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Cash from operating activities 50.91 M69.13 M86.69 M75.79 M134.59 M 183.5 M Cash from investing activities 1 M172.68 M17.05 M115.72 M302.44 M 28.82 M Cash from financing activities 278.98 M118.09 M3.08 M156.83 M337.25 M — Free cash flow 49.91 M60.02 M75.15 M73.02 M130.8 M 181.94 M

ニュース

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:FDMT) 2026-01-19

RBCキャピタル、4Dモレキュラー株に対し「アウトパフォーム」評価を32ドルで維持

RBC Capital reiterates Outperform rating on 4D Molecular stock at $32

4Dモレキュラー・セラピューティクスのアシュー・グプタ氏、FDMTの株式を330万ドル分売却

Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)

BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Aimei Health Technology (NASDAQ:AFJK), Aura Biosciences (NASDAQ:AURA)

Avago and Oracle among market cap stock movers on Wednesday

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential - Slideshow (NASDAQ:FDMT) 2025-12-17

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

4Dモレキュラー・セラピューティクス最高法務責任者、1万7千ドル相当の株式を売却